Lamotrigine in Parkinson's disease--a double blind study

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Antiglutamatergic agents show promise for Parkinson's disease (PD) hypokinesia in animal models.
• Existing antiglutamatergic drugs often act postsynaptically, exhibiting toxicity or limited clinical efficacy.
• Lamotrigine (LTG), an antiepileptic drug, uniquely inhibits presynaptic glutamate release, offering a potential novel therapeutic avenue for PD.

Purpose of the Study:

• To evaluate the efficacy and tolerability of Lamotrigine (LTG) as a treatment for Parkinson's disease (PD).
• To investigate LTG's potential to alleviate hypokinesia and other motor symptoms in PD patients.

Main Methods:

• A placebo-controlled trial was conducted with 20 patients diagnosed with Parkinson's disease (PD).
• Patients received either Lamotrigine (LTG) or a placebo.
• Efficacy was assessed through investigator's overall assessment and specific motor response parameters.

Main Results:

• Lamotrigine (LTG) was generally well-tolerated by the participants.
• A significant improvement was observed in the investigator's overall assessment of efficacy favoring LTG (6/10 vs. 2/10, p < 0.05).
• A trend towards beneficial effects was noted in some parameters, but no significant differences in motor response were detected between groups.

Conclusions:

• This study failed to confirm a strong antiparkinsonian effect of Lamotrigine (LTG).
• The findings suggest that larger patient cohorts are necessary to detect potential slight or moderate beneficial effects of LTG in Parkinson's disease (PD).
• Further research with increased sample sizes is warranted to fully elucidate LTG's therapeutic potential in PD.